タナカ　コウイチ   TANAKA Koh-ichi   田中　康一    所属   兵庫医科大学  薬学部 医療薬学科    職種   講師
言語種別	英語
発行・発表の年月	2022/06
形態種別	単行本
査読	査読あり
標題	Glycogen synthase kinase-3beta and methamphetamine abuse liability.
執筆形態	共著
掲載誌名	Advances in Health and Disease
掲載区分	国外
出版社・発行元	Nova Science Publishers, Inc. (New York)
巻・号・頁	55,pp.161-180
総ページ数	20
国際共著	国際共著
著者・共著者	◎Kitanaka J, Kitanaka N, Hall FS, Kountz LE, Hashimoto T, Hirabayashi K, Horie U, Iwasaki K, Kawasaki Y, Kimura M, Sakamoto T, Yashiro J, Tomita K, Igarashi K, Sato K, Tanaka K, Uhl GR, Nishiyama N.
概要	Glycogen synthase kinase-3 (GSK-3) (EC2.7.11.26) is an essential serine/threonine kinase that has a role in a variety of physiological processes. GSK-3 is constitutively active, multifaceted, and ubiquitous in nature. In mammalian cells, GSK-has two isoforms termed GSK-3alpha and GSK-3beta. GSK-3beta is present in high concentrations in tissues in the central nervous system, having a crucial role in neuronal signaling pathways. Abnormal activity of GSK-3 is associated with neurodegenerative disorders including Alzheimer’s disease and Parkinson’s disease. In neurodegenerative disorders, GSK-3beta enzyme levels are elevated, so that the inhibition of GSK-3beta might be expected to diminish signaling dysfunctions in these conditions. Differences in GSK-3β function occur in many psychiatric and neurological conditions as well, including drug dependence, perhaps because this signaling pathway influences cell survival and synaptic plasticity.
ISBN	978-1-68507-998-7
ISSN	2770-7385
PermalinkURL	https://doc-14-0s-apps-viewer.googleusercontent.com/viewer/secure/pdf/k4f2f10kejhl5vnab9rdjasdrb2go80n/6iu00ugjvij88jvhrru1ladr472tm92i/1657501425000/gmail/15420489316426386306/ACFrOgDmq22BjTn02G7gJzKaCOroaqlUvpIHWvwelvf2x1TeFsVNdg88S2v9mh-XIgojh1tQfzvc_8